European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.
Engelhardt
Monika
M
Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de
Udi
Josefina
J
Kleber
Martina
M
Spencer
Andrew
A
Rocci
Alberto
A
Knop
Stefan
S
Bruno
Benedetto
B
Bringhen
Sara
S
Pérez-Simón
José A
JA
Zweegman
Sonja
S
Driessen
Christoph
C
Patriarca
Francesca
F
Gramatzki
Martin
M
Terpos
Evangelos
E
Sezer
Orhan
O
Kropff
Martin
M
Straka
Christian
C
Johnsen
Hans E
HE
Waage
Anders
A
Boegsted
Martin
M
Lokhorst
Henk
H
Hájek
Roman
R
Morgan
Gareth
G
Boccadoro
Mario
M
Ludwig
Heinz
H
Cavo
Michele
M
Polliack
Aaron
A
Sonneveld
Pieter
P
Einsele
Hermann
H
Palumbo
Antonio
A
D002986:Clinical Trials as Topic / Q000379:methods*; D003245:Consensus Statements as Topic; D005060:Europe; D005104:Expert Testimony; D006801:Humans; D007255:Information Services; D009101:Multiple Myeloma / Q000628:therapy*; D012107:Research Design; D016879:Salvage Therapy